EQS-News / 14/06/2019 / 11:28 UTC+8
*14 June 2019 Press Release*
/
(Stock Code: 0690)
*Co-Construction of Healthcare Facilities for better Chronic Disease
Management in the Greater Bay Area,*
*Letter of Intent for Strategic Cooperation Framework Signed Between
Uni-Bio*
*Science and Kaiping Time City*
[14 June 2019 - Hong Kong] A fully integrated biopharmaceutical company -
Uni-Bio Science Group Limited (the "Company", together with its
subsidiaries, the "Group"; Stock code: 0690.HK), and its subsidiary, Uni-Bio
Science HealthCare Ltd. are pleased to announce that a Letter of Intent for
strategic cooperation framework has been signed with Kaiping Time City
Tourism Development Co., Ltd. ("the partner"). The Letter of Intent aims to
cooperate with the partner in the construction and operation of the chronic
illness rehabilitation base and related healthcare facilities combining with
the services of Chronic Disease Management.
Within the next 6 months, both parties will further evaluate the financial
feasibility of the project and finalize a deal structure that can better
leverage the strengths of each company and lead to a win-win partnership.
The successful signing of this cooperation will directly benefit the
long-term sales of the Group's chronic disease product portfolio, especially
the soon-to-launch rhExendin-4 ("Uni-E4") and rhPTH (1-34) ("Uni-PTH") to
treat diabetes and osteoporosis, respectively. Chronic diseases are
long-term conditions that usually progress slowly over time, therefore it is
often best managed through a comprehensive program that includes education
on health, proactive lifestyle changes, well-integrate primary care and
aftercare, and drug treatment. By working with our partner, we can integrate
our products in a broader chronic disease treatment solution for more
effective results for our patients. This approach also corresponds to the
strong support of Guangdong Province and local governments for the
development of great health industries.
On the signing of this Letter of Intent of the strategic cooperation, *Mr.
Kingsley Leung, Chairman of and Executive Director of Uni-Bio Science Group
Limited* said, "With the improvement of living standards and the arrival of
"aging China", the biggest problem threatening people's health is chronic
diseases. _The Outline of the 2030 Plan for Healthy China_ upgrades the
management and rehabilitation of chronic diseases to a new strategic level.
It is not only the needs of the country but also the demand of the people.
The Group's product line and innovative Biological drugs for the treatment
of chronic diseases will be released on the market in the near future,
providing a new avenue to treat these diseases that affect over 300 Million
people in China alone. It is worth emphasizing that Uni-PTH and Uni-E4 are
relatively new products in the Chinese market. They are cost-effective
products that solve unmet needs in osteoporosis and diabetes, respectively.
However, they are fairly expensive compared to common copy-cat chemical
drugs and will require education to physicians and patients on their
clinical uniqueness. This opportunity to expand our value-chain further
downstream to the private healthcare space will allow the Group to access
our target market directly and more cost-effectively. It will enable us to
better educate our customers, as well as receive feedback for our products
much quicker. Our partner is planning to invest up to RMB Six Billion Yuan
into the overall project. When completed, the project will attract
significant patient flow!
*Mr. Leung* continued: "The cooperation between the two sides not only has a
very good starting point, but also has a huge potential for further
development. In particular, the Group can also provide medical training for
health care institutions, technical and operational services for pre-market
phase I or post-market phase IV clinical trials of drugs, and can quickly
obtain first-hand clinical data for faster and more successful drug
development for the Group in the future. "
_- END -_
*About Uni-Bio Science Group Limited*
Uni-Bio Science Group Limited is principally engaged in the research and
development, manufacture and distribution of pharmaceutical products. The
research and development center is fully equipped with a complete system for
the development of genetically-engineered products with a pilot plant test
base which is in line with NMPA requirements. The Group also has two GMP
manufacturing bases in Beijing and Shenzhen. The Group is focused on the
development of novel treatments and innovative drugs addressing the
therapeutic areas of endocrine as diabetes and osteoporosis, ophthalmology
and dermatology.
Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong
Stock Exchange on November 12, 2001. Stock code: 0690.
For further information, please contact:
Jacob Zhang Phone: +86 10 6410 6099 Email: jacob.zhang@uni-bioscience.com
/
Document: http://n.eqs.com/c/fncls.ssp?u=SSEAFUJWIV [1]
Document title: Co-Construction of Healthcare Facilities for better Chronic
Disease Management in the Greater Bay Area, Letter of Intent for Strategic
Cooperation Framework Signed Between Uni-Bio Science and Kaiping Time City
14/06/2019 Dissemination of a Marketing Press Release, transmitted by EQS
Group.
The issuer is solely responsible for the content of this announcement.
Media archive at www.todayir.com
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ae2b818debad1efd279020baca25b493&application_id=824611&site_id=vwd&application_name=news
(END) Dow Jones Newswires
June 13, 2019 23:29 ET (03:29 GMT)
© 2019 Dow Jones News
